C4 Therapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 22, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| C4 Therapeutics, Inc. | ||
| Date: February 22, 2024 | By: | /s/ Andrew J. Hirsch |
|---|---|---|
| Andrew J. Hirsch | ||
| President and Chief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Andrew J. Hirsch | President, Chief Executive Officer, and Director | February 22, 2024 |
| Andrew J. Hirsch | (Principal Executive Officer) | |
| /s/ Kendra R. Adams | Chief Financial Officer and Treasurer | February 22, 2024 |
| Kendra R. Adams | (Principal Financial Officer) | |
| /s/ Mark Mossler | Chief Accounting Officer | February 22, 2024 |
| Mark Mossler | (Principal Accounting Officer) | |
| /s/ Bruce Downey | Chairman and Director | February 22, 2024 |
| Bruce Downey | ||
| /s/ Kenneth C. Anderson, M.D. | Director | February 22, 2024 |
| Kenneth C. Anderson, M.D. | ||
| /s/ Laura Bessen, M.D. | Director | February 22, 2024 |
| Laura Bessen, M.D. | ||
| /s/ Glenn Dubin | Director | February 22, 2024 |
| Glenn Dubin | ||
| /s/ Donna Grogan, M.D. | Director | February 22, 2024 |
| Donna Grogan, M.D. | ||
| /s/ Owen Hughes | Director | February 22, 2024 |
| Owen Hughes | ||
| /s/ Utpal Koppikar | Director | February 22, 2024 |
| Utpal Koppikar | ||
| /s/ Malcolm Salter | Director | February 22, 2024 |
| Malcolm Salter | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Report of Independent Registered Public Accounting Firm | F-2 |
|---|---|
| Consolidated Balance Sheets | F-3 |
| Consolidated Statements of Operations and Comprehensive Loss | F-4 |
| Consolidated Statements of Stockholders’ Equity | F-5 |
| Consolidated Statements of Cash Flows | F-6 |
| Notes to Consolidated Financial Statements | F-8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.